CagriSema_Dosage, benefits & legal status
Also known as cagrilintide and semaglutide, Cagrilintide + Semaglutide, Semaglutide + Cagrilintide, cagri sema, CagriSema blend, GLP-1 C/S
A weekly two-in-one shot combining cagrilintide and semaglutide for bigger loss.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is CagriSema?
Plain language first. The technical label stays, but it never stands alone.Overview
It hits two separate fullness pathways at once for bigger weight loss than either alone. It is still experimental.
CagriSema is a fixed combination of cagrilintide (an amylin copy) and semaglutide (a GLP-1 copy) in one weekly shot.
What it's used for
A weekly two-in-one shot combining an appetite-lowering peptide with semaglutide, for bigger weight loss than either alone.
How does CagriSema work?
What it does in the body, and where.CagriSema is two drugs in one weekly injection: cagrilintide and semaglutide, at fixed doses. The logic is that two separate fullness pathways should add up.
- 01Semaglutide handles the GLP-1 sideAppetite, stomach emptying, blood sugar.
- 02Cagrilintide handles the amylin sideA different route to fullness, so the two do not compete for the same receptor.
- 03Fixed doses, titrated togetherBoth components rise on one schedule over roughly 16 weeks, so you cannot adjust one without the other.
- 04Filed with the FDA, not approvedThe application went in during December 2025. Until a decision, this remains investigational.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Weight loss in adults without diabetes (REDEFINE 1)
Investigational- Human trial3,417 adults with overweight or obesity and no diabetes were randomized for 68 weeks; 2,108 were assigned to the combination.
- Human trialAverage weight change was -20.4% on the combination against -3.0% on placebo, counting everyone randomized (a difference of 17.3 points, P<0.001).
- Human trialStomach and gut side effects affected 79.6% against 39.9% on placebo, mostly mild to moderate and passing.
Women across menopause stages (post hoc, sponsor-reported)
Investigational- Human trialAcross the 2,309 women in REDEFINE 1, Novo Nordisk reported average weight loss at 68 weeks of 25.0% on the combination against 3.0% on placebo.
- Human trialSplit by menopause stage in 1,902 women, it reported 26.7% against 2.1% before menopause, 24.8% against 1.7% in perimenopause and 23.1% against 2.6% after menopause.
- No dataThese figures use the efficacy estimand, a model that assumes everyone stayed on treatment without other weight-loss therapy, so they run higher than the trial's main 20.4% result.
- No dataMenopause stage was assigned afterward from age, medical history and recorded symptoms. The p-values were not adjusted for multiple comparisons and the stages were not tested against each other, so the analysis cannot show the drug works better in one stage than another.
- No dataWomen using hormone therapy were analyzed as a separate group, and the release gives no results for them. It reports weight and waist measures only, with nothing on hot flashes or other menopause symptoms.
The published record
Papers and trials about CagriSema
Searched: CagriSema, cagrilintide and semaglutide, Cagrilintide + Semaglutide, Semaglutide + Cagrilintide, cagri sema, CagriSema blend.
85 papers tagged human · 21 not reviews or lab · 12 clinical trial publications
33 registered trials · 1 with posted results
Furthest stage reached: Phase 3, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about CagriSema
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
10 mg
Half-life
6 to 8 days for both parts
How much, and do you cycle it?
The range, and whether you take breaks.2.4 mg cagrilintide plus 2.4 mg semaglutide per week, weekly. Not cycled in the trials Trial dose
Given continuously for the whole study period: REDEFINE 1, 68 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.
6 to 8 days for both partsTrial protocol
Cagrilintide and semaglutide in one injection. Measured together in the same trial, cagrilintide runs about 159 to 195 hours and semaglutide about 145 to 165. They happen to be close, which is why weekly dosing works for the pair.
Source: Enebo LB et al., Lancet 2021;397:1736-1748 (PMID 33894838)
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Unlike the community blends, this ratio is not a vendor choice. CagriSema is a fixed 1:1 co-formulation and the trials that produced its results used 2.4 mg of each. Research-market vials are usually labeled 5/5 or 10/10, which describes the vial rather than a dose. Read the per-component milligrams off your label, because a vial marked 10 mg total holds 5 mg of each.
Pick your vial to see concentrations and a draw.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
Your draw
What one draw delivers
The same arithmetic as the calculator, worked out for the vials vendors sell.Dose anchored to Semaglutide, at the commonly cited 2.4 mg per week. Each table assumes one draw per week. If you split it across more injections, divide the reading by the number of injections.
| Semaglutide dose | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 2.4 mg | 48.0 units
| 96.0 units
| Over 100 units: will not fit one U-100 syringe.
|
| Semaglutide dose | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 2.4 mg | 24.0 units
| 48.0 units
| 72.0 units
|
| Semaglutide dose | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 2.4 mg | 100.0 units
| Over 100 units: will not fit one U-100 syringe.
| Over 100 units: will not fit one U-100 syringe.
|
The ratio is fixed at 1:1, so a draw giving 2.4 mg of semaglutide gives 2.4 mg of cagrilintide with it. That is the pairing REDEFINE 1 tested, and it is the one case in this library where a blend's ratio comes from a trial protocol rather than from whoever filled the vial.
CagriSema starts at $44.54 across 19 vendors, typically $6.60 – $14.40 per mg.
26 listings, last read Oct 24, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized CagriSema keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- A personal or family history of medullary thyroid cancer, or MEN 2
- Pregnancy
Stop and get help
- Severe stomach pain that spreads to your back
- A lump or swelling in your neck, hoarseness, or trouble swallowing
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Stomach effects hit about 80% of people in trials, against 40% on placebo
- Nausea in roughly 55%, constipation 31%, vomiting 26%
- About 6% stopped because of side effects
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is CagriSema approved?
And where the numbers on this page come from.No. CagriSema is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked21 October 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
More on CagriSema
- CagriSema prices
- CagriSema 10 mg priceWhat every tracked vendor charges for a 10 mg CagriSema vial, which ones show testing evidence.
- CagriSema 20 mg priceWhat every tracked vendor charges for a 20 mg CagriSema vial, which ones show testing evidence.
- CagriSema Lost Its Head-to-Head. The Filing Is UnaffectedIt missed non-inferiority in the only direct comparison. The filing is unaffected, because approval and beating the market leader are different questions.
- CagriSema: what the REDEFINE trials foundThe only peptide stack tested against each of its compounds alone. 22.7% weight loss against 16.1% for semaglutide, which is 88% of additive.
- When Will CagriSema Be Approved? What Novo Has FiledNovo filed in December 2025 and expects a decision in Q4 2026. No PDUFA date is public. The application rests on REDEFINE 1 and 2, not the trial it lost.
- Does CagriSema Reduce Food Noise? What the Brain Scan Actually MeasuredNovo says CagriSema reduced food noise in a 52-week fMRI study. It published no score for that finding and did not name the instrument it used to measure it.
What else is like CagriSema?
Others in Amylin analogs, side by side.If you're weighing CagriSema, it's worth reading Retatrutide + Cagrilintide blend, Petrelintide, and Amycretin in the same class.
A weekly two-in-one shot combining cagrilintide and semaglutide for bigger loss.
- Dose
- 2.4 mg cagrilintide plus 2.4 mg semaglutide per week
- How often
- Weekly
An unapproved triple agonist paired with an amylin analog, tested by nobody.
- Dose
- Research only
- How often
- Weekly, by convention
An experimental weekly fullness-hormone shot for weight loss.
- Dose
- 1.0 up to 9.0 mg per week (trial maintenance doses, not an approved dose)
- How often
- Weekly
An experimental two-in-one weight-loss compound, as a pill or a shot.
- Dose
- 0.3 up to 60 mg per week
- How often
- Once weekly (injected)
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Garvey WT et al., N Engl J Med 2025;393:635-647 (REDEFINE 1)(2025)3,417 adults randomized for 68 weeks; -20.4% with the combination against -3.0% with placebo (treatment-policy estimand); gut side effects 79.6% against 39.9%.
- Novo Nordisk, post hoc analysis of REDEFINE 1 in women (October 20, 2026)(2026)Efficacy-estimand weight loss at week 68: all women 25.0% against 3.0%; premenopausal 26.7% against 2.1%, perimenopausal 24.8% against 1.7%, postmenopausal 23.1% against 2.6%. Status derived post hoc; no multiplicity adjustment or interaction tests. FDA decision expected in the fourth quarter of 2026.
- ClinicalTrials.gov NCT05567796 (REDEFINE 1)(2026)Phase 3 trial of CagriSema 2.4 mg/2.4 mg once weekly in adults with overweight or obesity; active, not recruiting; no results posted.
- Enebo LB et al., Lancet 2021;397:1736-1748(2021)Phase 1b trial of cagrilintide given with semaglutide 2.4 mg; the source of the half-life figures on this page.
Beyond these, 122 records are indexed. Browse the records
Novo says CagriSema reduced food noise but names no measurement instrument, although a validated Food Noise Questionnaire exists. Our guide examines the food noise claim, and the instrument question behind it.